These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6530609)

  • 1. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.
    Ogasahara S; Nishikawa Y; Takahashi M; Wada K; Nakamura Y; Yorifuji S; Tarui S
    J Neurol Sci; 1984; 66(2-3):151-63. PubMed ID: 6530609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T; Kishikawa H
    Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of supplemental carbidopa on bioavailability of L-dopa.
    Cedarbaum JM; Kutt H; Dhar AK; Watkins S; McDowell FH
    Clin Neuropharmacol; 1986; 9(2):153-9. PubMed ID: 3085927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
    Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
    Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAO and L-dopa treatment of Parkinson's disease.
    Tyce GM; Dousa MK; Muenter MD
    J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
    Extein I; Van Woert M; Roth RH; Bowers MB
    Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
    Spencer SE; Wooten GF
    Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
    Melamed E; Bitton V; Zelig O
    Neurology; 1986 Jan; 36(1):100-3. PubMed ID: 3941762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 15. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD; McDowell FH; Wasterlain CG; Stern PH
    Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Gervas JJ; Muradás V; Bazán E; Aguado EG; de Yébenes JG
    Neurology; 1983 Mar; 33(3):278-82. PubMed ID: 6681870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.